User: Guest  Login
Title:

Actionable loss of SLF2 drives B-cell lymphomagenesis and impairs the DNA damage response.

Document type:
Journal Article; Research Support, Non-U.S. Gov't
Author(s):
Zhang, Le; Wirth, Matthias; Patra, Upayan; Stroh, Jacob; Isaakidis, Konstandina; Rieger, Leonie; Kossatz, Susanne; Milanovic, Maja; Zang, Chuanbing; Demel, Uta; Keiten-Schmitz, Jan; Wagner, Kristina; Steiger, Katja; Rad, Roland; Bassermann, Florian; Müller, Stefan; Keller, Ulrich; Schick, Markus
Abstract:
The DNA damage response (DDR) acts as a barrier to malignant transformation and is often impaired during tumorigenesis. Exploiting the impaired DDR can be a promising therapeutic strategy; however, the mechanisms of inactivation and corresponding biomarkers are incompletely understood. Starting from an unbiased screening approach, we identified the SMC5-SMC6 Complex Localization Factor 2 (SLF2) as a regulator of the DDR and biomarker for a B-cell lymphoma (BCL) patient subgroup with an adverse...     »
Journal title abbreviation:
EMBO Mol Med
Year:
2023
Journal volume:
15
Journal issue:
9
Fulltext / DOI:
doi:10.15252/emmm.202216431
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/37485814
Print-ISSN:
1757-4676
TUM Institution:
Institut für Allgemeine Pathologie und Pathologische Anatomie (Dr. Mogler komm.); Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie (Prof. Bassermann); Klinik und Poliklinik für Nuklearmedizin (Prof. Weber); Professur für Molekulare Onkologie und Funktionelle Genomik (Prof. Rad)
 BibTeX